Pelthos Therapeutics — Third Quarter 2026 Earnings Summary

Pelthos Therapeutics reported third-quarter 2026 net product revenue of $15.2 million for Zelsuvmi, representing an 114% increase from the same period in 2025. The company dispensed 12,384 units of Zelsuvmi to 4,942 unique prescribers while expanding formulary coverage to 127 million commercially covered lives. On October 30, 2026, Pelthos announced a definitive merger agreement with Castle Creek Biosciences to create a diversified biotechnology company focused on serious skin diseases, with the transaction expected to close by the end of the first quarter of 2027. For the quarter, the company recorded a net loss of $7.9 million and held a cash balance of $17.7 million as of September 30, 2026.